Invex Therapeutics Ltd. · ASX:IXC

Invex Therapeutics — Bell Potter Healthcare Conference 2020

11 slides from Invex Therapeutics's conference presentation, Nov 26, 2020

  1. Slide 1: Invex Therapeutics

    Invex Therapeutics Bell Potter Healthcare Conference 26 November 2020 ASX Code: IXC

  2. Slide 2: Disclaimer

    Disclaimer This presentation (Presentation) is issued by Invex Therapeutics Ltd (ASX:IXC) (the Company or IXC). The information presented in this Presentation may contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on rea

  3. Slide 3: Company Snapshot

    Company Snapshot Company Major Shareholders Repurposed Proven Drug Presendin™ (Exenatide) Directors / Management 16.8% Tattarang 11.8% Clinical Stage Entering Phase III Tisia Nominees Pty Ltd 5.3% Idiopathic Intracranial Orphan Disease Focus Hypertension (IIH) JK Nominees Pty Ltd 5.0% Orphan Designa

  4. Slide 4: A clinician's perspective on Idiopathic Intracranial Hypertension (IIH)

    A clinician’s perspective on Idiopathic Intracranial Hypertension (IIH) Professor Alexandra J. Sinclair MBChB, MRCP, PhD  Institute of Metabolism and Systems Research  Professor of Neurology, University of Birmingham  Chief Scientific Officer & Executive Director Invex Therapeutics 4

  5. Slide 5: Invex Therapeutics - Executive Summary

    Invex Therapeutics - Executive Summary Clinical stage drug development Company targeting the orphan disease Idiopathic Intracranial Hypertension (IIH) Attractive Market Dynamics  IIH Total Addressable Market (TAM) in the US and Europe of A$1.6 billion per annum and growing at 3.4% per annum  Unenc

  6. Slide 6: What is Idiopathic Intracranial Hypertension (IIH)?

    What is Idiopathic Intracranial Hypertension (IIH)? The Disease1  >90% of cases are overweight women of childbearing age, with no known cause (idiopathic): approx. 4.7 per 100,000  >90% suffer headaches that are progressively more severe and frequent: major cause of morbidity  Up to 25% suffer pe

  7. Slide 7: Invex Phase II trial – design & outcomes

    Invex Phase II trial – design & outcomes Study Purpose  Obtain first clinical proof of concept for Exenatide in IIH and provide a basis to move into pivotal Phase III trial by leveraging orphan drug status in Europe and the United States Efficacy Outcomes  Primary Endpoint (reduction in ICP) Met –

  8. Slide 8: Regulatory update

    Regulatory update Strength of the outcomes for both primary & key secondary clinical endpoints from the Phase II study implies a clear & strong drug effect in the IIH population & supports progression to a Phase III clinical trial for registration in the USA and EU European Medicines Agency US Food

  9. Slide 9: Summary & Outlook

    Summary & Outlook  Large, growing market for IIH with no approved medical interventions  Orphan Drug Designation in the USA and EU provides expedited, cost-effective clinical trial recruitment, reporting and approval/registration as well as commercial exclusivity for up to 10 years  Strong Phase

  10. Slide 10: Thank you

    cue Thank you invex THERAPEUTICS

  11. Slide 11: Contacts

    Contacts INVESTORS MEDIA Dr Tom Duthy Margie Livingston Executive Director Ignite Communications +61 402 493 727 +61 438 661 131 tduthy@invextherapeutics.com margie@ignitecommunications.com .au To subscribe to Invex email alerts, please visit www.invextherapeutics.com Follow us on Twitter @InvexTher

Invex Therapeutics — Bell Potter Healthcare Conference 2020 on 6ix